Related Experiment Video
Updated: May 27, 2025

Intranasal Administration of CNS Therapeutics to Awake Mice
Published on: April 8, 2013
Efficacy of hypertonic nasal spray with algae in rhinosinusitis
Zeynel Öztürk1, Nuray Bayar Muluk2,3, Rahime Koca4
1Istanbul Nişantaşı University, Faculty of Medicine, Department of Otorhinolaryngology and Baypark Hospital, Otolaryngology Clinics, Istanbul, Turkey.
Objectives:
We aimed to evaluate the effectiveness of nasal irrigation sprays at treating rhinosinusitis by easing congestion in the nose and other symptoms.
Methods:
A total of 1700 individuals diagnosed with rhinosinusitis were assigned to the following groups: One group used Sinomarin® hypertonic nasal spray (n = 600), another used Sinomarin® Plus Algae ENT hypertonic nasal spray (n = 600), and a third used an isotonic saline nasal spray (n = 500). Before and after therapy, patients had their symptoms and turbinates examined, overall symptoms scored, and quality of life (QoL) evaluated.
Results:
The findings showed that both groups saw a decrease in symptom scores for anterior discharge, postnasal drip, headache, and obstruction with therapy, as well as an improvement in turbinate color and edema (p < 0.05). Quality of life (QoL) ratings rose, and total symptom scores fell during therapy. The group that used hypertonic nasal spray with algae had considerably fewer overall symptom scores than the other groups (hypertonic nasal spray and saline). The hypertonic nasal spray group reported substantially fewer symptoms than the saline group. For what concerns quality of life, the saline group had significantly worse scores than groups 1 and 2; groups 1 and 2 were similar to one another.
Conclusion:
We found that compared to hypertonic and saline nasal sprays, the algae-containing hypertonic spray reduced total symptom scores more than the other sprays. This indicated that irrigation based on algae-containing hypertonic nasal sprays could be the treatment of choice for the management of symptoms in rhinosinusitis patients.
Clinical Trial Number:
The study was registered to ClinicalTrials.gov Protocol Registration and Results System (PRS) with a Clinical trial number of E-95961207-202.3.02-2955.
Related Concept Videos
Epistaxis
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Suctioning the Nasopharyngeal Airway
Equipment Required

